

# Phytochemicals and Molecular Docking: A Futuristic Approach for Drug Discovery

<sup>1</sup>Atul Kaushik, <sup>2</sup>Jeevan Jyoti Kaushik and <sup>3</sup>Nand Lal

<sup>1</sup>School of Applied Chemistry & Basic Sciences, Sardar Bhagwan Singh University, Balawala, Dehradun, Uttarakhand, India

<sup>2</sup>Department of Microbiology, School of Basic and Applied Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India

<sup>3</sup>School of Life Sciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India

## ABSTRACT

The increasing prevalence of drug resistance and adverse effects associated with synthetic drugs has intensified the search for novel therapeutic agents from natural sources. Phytochemicals, bioactive compounds derived from plants, have gained renewed interest due to their diverse chemical structures and broad-spectrum pharmacological activities. Current researchers integrate traditional ethnobotanical knowledge with advanced computational techniques, particularly molecular docking, to expedite the drug discovery process. Molecular docking enables the prediction of interactions between phytochemicals and biological targets, streamlining the identification of potential drug candidates. Recent studies have successfully applied molecular docking to identify promising anti-cancer, anti-microbial, and anti-inflammatory agents from plants. Furthermore, docking combined with molecular dynamics simulations and *in silico* ADME (Absorption, Distribution, Metabolism, and Excretion) studies has improved the reliability of these findings. The application of artificial intelligence and machine learning in docking is also enhancing accuracy and predictive power. This review explores the synergy between phytochemicals and molecular docking, highlighting current research trends and emerging challenges. By bridging traditional plant-based therapeutics with modern computational tools, this approach offers a promising pathway for developing effective, safe, and affordable drugs to address global health challenges.

## KEYWORDS

Drug discovery, drug target, phytochemical, molecular docking, plant-based therapy

Copyright © 2025 Kaushik et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION

The rise of antimicrobial resistance poses a significant threat to global health, as pathogens evolve and become increasingly resistant to existing treatments, leading to a high rate of treatment failures and mortality. The development of new antimicrobial agents that can combat drug-resistant organisms is urgently needed. The quest for novel therapeutic agents has entered a transformative era, largely driven by advancements in phytochemistry and computational biology. Phytochemicals, bioactive compounds derived from plants, have long been recognized for their potential medicinal properties, offering diverse mechanisms of action that could lead to effective treatments for various diseases<sup>1</sup>. As the complexity of



drug interactions and target specificity becomes increasingly apparent, the integration of molecular docking techniques emerges as a pivotal strategy in drug discovery<sup>2</sup>. This computational approach allows researchers to predict the interaction between phytochemicals and biological targets at the molecular level, facilitating the identification of promising candidates for further development. The fusion of traditional phytochemical knowledge with modern technology is revolutionizing the field, enabling the discovery of innovative, nature-inspired solutions. A wide variety of protective phytochemicals in fruits, vegetables, whole grains, nuts, legumes, and herbal seasonings, the regular consumption of these foods is essential to ensuring a healthier population that has lower rates of heart disease and cancer<sup>3</sup>. The traditional drug development process, which typically spans 10-15 years, is both time-consuming and costly, often exceeding billions of dollars. Despite these investments, the failure rate remains high due to factors such as poor efficacy, adverse side effects, and the emergence of drug resistance, particularly in infectious diseases and cancers<sup>4</sup>. The growing burden of chronic diseases like cancer, diabetes, and neurodegenerative disorders demands innovative therapeutic approaches. Conventional synthetic drugs, while effective in many cases, can lead to adverse reactions, toxicity, and reduced efficacy over time. These challenges have intensified the need for discovering novel therapeutic agents with unique mechanisms of action and fewer side effects. In this context, natural products, especially phytochemicals, have emerged as a promising source of new drug candidates. Medicinal plants are incorporated in our day-to-day lives and help boost immunity and provide the best nutrition to fight against infections<sup>5</sup>. This study aims to evaluate the drug-likeness of phytochemicals by utilizing molecular docking approaches to identify their binding potential with target proteins, thereby supporting their role in futuristic drug discovery.

**Importance of phytochemicals in modern medicine:** Phytochemicals are naturally occurring bioactive compounds found in plants. These secondary metabolites, which include alkaloids, flavonoids, terpenoids, phenolics, and glycosides, serve various ecological functions such as defense against pathogens, UV protection, and pollinator attraction<sup>6</sup>. Over centuries, traditional systems of medicine like Ayurveda, Traditional Chinese Medicine (TCM), and African traditional medicine have utilized plants to treat a wide range of diseases. The scientific validation of these traditional practices has led to the discovery of many lead compounds for modern drug development. Phytochemicals are valued for their structural diversity and biological activity, which provide a vast chemical library for drug discovery<sup>7</sup>. Unlike synthetic compounds, phytochemicals are often more biocompatible and may exhibit multi-target mechanisms of action. This polypharmacology is particularly useful for treating complex diseases like cancer, where targeting multiple pathways simultaneously can improve therapeutic outcomes<sup>8</sup>.

**Natural compound classes and their translational potential in drug development:** Medicinal plants are well-established sources of diverse bioactive phytochemicals, including flavonoids, alkaloids, terpenoids, glycosides, and phenolic compounds. These natural constituents have long been utilized in traditional medicine and are increasingly investigated for their therapeutic potential using modern scientific tools. Among these, molecular docking has emerged as a powerful *in silico* technique for identifying lead compounds by simulating their binding affinities with specific biomolecular targets. Recent studies have demonstrated the antimicrobial potential of *Alseodaphne andersonii*, supported by significant inhibitory activity against multiple pathogenic bacterial strains<sup>9</sup>. Similarly, the roots of *Tectona grandis* have shown promising antitussive effects in *in vivo* models, validating their traditional use<sup>10</sup>. The antioxidant capacity and CNS-stimulant properties of *Diplazium esculentum* have also been confirmed through FRAP assays and behavioral studies<sup>11</sup>. Additionally, *Cyphostemma adenocoule* has exhibited substantial phospholipase A2 inhibitory activity, reinforcing its Ethnomedicinal application in the management of snake envenomation<sup>12</sup>. Furthermore, recent molecular docking-based screening identified a novel inhibitor of Cytosolic Phospholipase A2 (cPLA2) with a docking score superior to the known inhibitor ATK. This compound also demonstrated favorable ADME, drug-likeness, and toxicity profiles, making it a promising




Fig. 1: Flowchart diagram of the process of phytochemicals to molecular modeling

candidate for further structure-activity relationship (SAR) optimization and preclinical evaluation as an anti-epileptic agent<sup>13</sup>. These findings collectively highlight the value of integrating traditional botanical knowledge with computational tools to accelerate the discovery and development of phytochemical-based therapeutics targeting infectious, inflammatory, and neurological disorders.

**Role of computational tools in drug discovery:** In the past two decades, computational tools have become integral to the drug discovery pipeline. Molecular docking, molecular dynamics simulations, and *in silico* ADME/Toxicity predictions help streamline the identification of potential drug candidates by reducing the need for extensive *in vitro* and *in vivo* testing. These tools allow researchers to predict the binding affinity of compounds to target proteins, understand molecular interactions at an atomic level, and optimize lead compounds before synthesis and testing<sup>14</sup>. Molecular docking, in particular, has emerged as a powerful tool for identifying potential therapeutic agents from large libraries of phytochemicals. Docking can predict the stability, binding mode, and potential efficacy of the compound. This approach accelerates the identification of promising leads, reduces costs, and allows for the exploration of compounds that may be challenging to synthesize in a laboratory setting<sup>15</sup>.

**Molecular docking and dynamics study of phytochemicals:** Given the convergence of traditional knowledge, phytochemical diversity, and computational advancements, the integration of phytochemicals and molecular docking (Fig. 1) offers a futuristic and promising approach to drug discovery. Numerous plant-derived phenolic compounds have exhibited wide-ranging biological activities of medicinal importance. Some notable examples include the stilbenoid resveratrol, Curcumin, Quercetin etc, which has shown numerous potential health benefits, including anti-carcinogenic activity (Table 1).

The process of phytochemical molecular docking involves several key steps aimed at understanding how natural compounds interact with biological targets. First, phytochemical selection involves identifying bioactive compounds from natural sources. Once selected, the preparation of the phytochemical follows, where the compound's structure is converted into a 3D format and optimized using molecular modeling software. The next step is target protein selection, where a relevant biological protein (such as a receptor or enzyme) is chosen, and its 3D structure is obtained, often from resources like the Protein Data Bank.

Table 1: Phytochemicals and their molecular docking studies

Phytochemical	Source plant	Target protein	Binding energy (kcal/mol)	Potential application	References
Curcumin	<i>Curcuma longa</i>	NF- $\kappa$ B (p65 subunit)	-5.42	Anti-inflammatory, Anti-cancer	Cheemanapalli <i>et al.</i> <sup>16</sup>
Quercetin	<i>Allium cepa</i> , <i>Citrus spp.</i>	SARS-CoV-2 3CL protease	-8.58	Antiviral (COVID-19)	Gasmi <i>et al.</i> <sup>17</sup>
Berberine	<i>Berberis vulgaris</i>	HSD11B1	-8.7	Antipsychotic-induced metabolic syndrome	Huang and Liu <sup>18</sup>
Resveratrol	<i>Vitis vinifera</i>	MeCP2	-94.76	Cancer inhibition pathway	Sahu <i>et al.</i> <sup>19</sup>
Epigallocatechin Gallate (EGCG)	<i>Camellia sinensis</i>	NLRP3	-9.6	Cellular injury	Jena <i>et al.</i> <sup>20</sup>
Taxol (Paclitaxel)	<i>Taxus brevifolia</i>	$\beta$ -Tubulin	-10.2	Anti-cancer (Mitotic inhibitor)	Yang <i>et al.</i> <sup>21</sup>
Betulinic acid	<i>Betula alba</i>	Autocrine Motility Factor Receptor	-7.22	Refractory tumors	Saeed <i>et al.</i> <sup>22</sup>
Ginsenoside- Rb1 & Rb2	<i>Panax ginseng</i>	BACE1	-10.0	Alzheimer's disease	Choi <i>et al.</i> <sup>23</sup>
Hesperidin	<i>Citrus sinensis</i>	PLK1 and EGFR	-9.0	Cytoprotective	Rizvi <i>et al.</i> <sup>24</sup>
Allicin	<i>Allium sativum</i>	FtsZ	-10.0	Antibacterial, Antimicrobial	Cahayani <i>et al.</i> <sup>25</sup>
Piperine	<i>Piper nigrum</i>	TRPV1 (Transient receptor potential channel)	-7.9	Analgesic, Anti-inflammatory	Karunakar <i>et al.</i> <sup>26</sup>

Table 2: Future perspectives on phytochemicals and molecular docking in drug discovery

Future perspective	Description	Potential impact	Major software/platforms
AI and machine learning integration	AI to predict binding affinities and pharmacokinetics of phytochemicals	Accelerates screening and lead identification, reducing time and cost	DeepDock, AlphaFold, DeepChem, AutoQSAR
Hybrid drugs (phytochemical and synthetic)	Combining phytochemicals with synthetic drugs to improve efficacy and reduce side effects	Enhances therapeutic potential through synergistic action	AutoDock, AutoDock Vina, Molecular Operating Environment (MOE)
Personalized medicine	Tailoring phytochemical therapies based on individual genetic profiles	Optimizes treatment outcomes for specific populations	OpenEye, Schrödinger's Maestro, DockThor
Nanotechnology-based delivery	Developing nanoparticles and liposomes to enhance phytochemical bioavailability	Improves stability, targeted delivery, and therapeutic efficacy	NanoDDS, Arguslab, GROMACS, LAMPPS
Focus on neglected diseases	Identifying phytochemicals for treating rare and neglected diseases	Addresses gaps in research for underserved medical conditions	PyRx, iGEMDOCK, Docking Server
Multi-target drug discovery	Identifying phytochemicals that interact with multiple molecular targets	Effective for treating complex diseases like cancer and neurodegeneration	AutoDock Vina, Glide (Schrödinger), FlexX
<i>In-Silico</i> toxicity and ADMET prediction	Using computational tools to predict safety and pharmacokinetics of phytochemicals	Enhances safety profiles and reduces preclinical failures	Swiss ADME, pkCSM, ADMET Predictor
Virtual reality (VR) in docking	Using VR for 3D visualization of phytochemical-protein interactions	Improves understanding and design of targeted therapies	Nanome, Covalent docking with ChimeraX, VR-Vina
Expanding Plant Databases	Growing phytochemical databases with new plant species and compounds	Facilitates the discovery of novel therapeutic agents	ChEMBL, PubChem, IMPPAT, NPASS

In protein preparation, the protein structure is cleaned by removing water molecules and ligands, and hydrogen atoms are added to correct the charges. The docking setup phase defines the binding site on the target protein, and docking parameters are chosen, followed by the use of suitable software for the simulation. The molecular docking simulation predicts how the phytochemical interacts with the protein by running the docking algorithm. Afterward, results analysis is carried out to evaluate the binding energy

scores and to examine hydrogen bonding and other molecular interactions. The results are then visualized and validated using software like PyMOL or Chimera, ensuring the docking predictions align with experimental data. Finally, the findings are reported and interpreted, with recommendations for possible therapeutic applications of the phytochemical based on its binding potential.

### **FUTURE PERSPECTIVES**

Future outlooks point to a revolutionary change in pharmacological methods as scientists continue to investigate the enormous potential of phytochemicals and molecular docking in drug discovery. The identification and optimization of lead compounds from natural sources could be made easier by combining cutting-edge computational methods with phytochemical studies. Scientists may make previously unheard-of predictions about how bioactive phytochemicals and target proteins will interact by using molecular docking simulations. In addition to increasing the effectiveness of medication design procedures, this collaboration opens the door for the development of new therapeutic medicines with fewer adverse effects. Furthermore, the growing emphasis on personalized medicine reinforces the need for tailored phytochemical applications, which can be achieved through targeted molecular docking studies. Collectively, these advancements signal a promising future where the amalgamation of phytochemical research and cutting-edge technology revolutionizes drug discovery paradigms, ultimately benefiting global health (Table 2).

### **CONCLUSION**

In conclusion, the integration of phytochemicals with molecular docking represents a transformative approach in drug discovery, particularly in identifying novel therapeutic agents against complex diseases such as cancer. The findings underscore the therapeutic potential of various phytochemicals, such as Kushenol T and Neocalyxins A, which exhibit strong binding affinities to critical proteins like CDK2, a key player in cancer progression. Furthermore, the utility of advanced computational methods not only accelerates the identification of these bioactive compounds but also enhances their specificity and efficacy, as illustrated by the exploration of phytochemicals targeting the Bile Salt Export Pump (BSEP) in cholestasis treatment. This dual focus on phytochemicals and molecular docking paves the way for more effective, safe, and individualized therapies, heralding a new era in pharmacology that aligns with the urgent need for innovative solutions in healthcare.

### **SIGNIFICANCE STATEMENT**

The application of advanced computational methods not only expedites the identification process but also enhances the efficacy and specificity of various bioactive compounds. This simultaneous focus on phytochemicals and molecular docking opens the way to safer, more customized, and more effective medicines by predicting which phytochemicals are likely to demonstrate efficacy, especially in novel or developing disorders. Additionally, it marks the beginning of a new age in pharmacology that aligns with the urgent need for innovative solutions in the medical field.

### **ACKNOWLEDGMENT**

The authors are thankful to the people who are directly or indirectly involved in the preparation of the manuscript.

### **REFERENCES**

1. Nahar, L. and S.D. Sarker, 2024. Computational Phytochemistry: An Overview. In: Computational Phytochemistry, Sarker, S.D. and L. Nahar (Eds.), Elsevier, Amsterdam, Netherlands, ISBN: 978-0-443-16102-5, pp: 1-58.
2. Lin, X., X. Li and X. Lin, 2020. A review on applications of computational methods in drug screening and design. *Molecules*, Vol. 25. 10.3390/molecules25061375.

3. Craig, W.J., 1997. Phytochemicals: Guardians of our health. J. Am. Diet. Assoc., 97: S199-S204.
4. Petrova, E., 2013. Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. In: Innovation and Marketing in the Pharmaceutical Industry: Emerging Practices, Research, and Policies, Ding, M., J. Eliashberg and S. Stremersch (Eds.), Springer, New York, ISBN: 978-1-4614-7801-0, pp: 19-81.
5. Singh, G., P. Sahu, A. Sharma, B. Butool, R. Sarkar, R. Mishra and R. Soni, 2022. Public awareness about the usage of medicinal herbs found in the kitchen and their potential against COVID-19 disease. Plant Arch., 22: 288-296.
6. Bidlack, W.R. and W. Wang, 2000. Designing Functional Foods to Enhance Health. In: Phytochemicals as Bioactive Agents, Bidlack, W.R., S.T. Omaye, M.S. Meskin and D.K.W. Topham (Eds.), CRC Press, Boca Raton, Florida, ISBN: 9780429181252, pp: 241-270.
7. Ansari, S., 2021. Overview of Traditional Systems of Medicine in Different Continents. In: Preparation of Phytopharmaceuticals for the Management of Disorders: The Development of Nutraceuticals and Traditional Medicine, Egbuna, C., A.P. Mishra and M.R. Goyal, Elsevier, Amsterdam, Netherlands, ISBN: 978-0-12-820284-5, pp: 431-473.
8. Macht, D.I., 1930. Contributions to phytopharmacology or the applications of plant physiology to medical problems. Science, 71: 302-306.
9. Parcha, V., A. Kaushik, J.J. Kaushik, M.S.M. Rawat, S.A.S. Biswas, 2007. Evaluation of antimicrobial potential of *Alseodaphne andersonii*. leaf extracts against pathogenic bacteria. Pharm. Biol., 45: 60-63.
10. Kaushik, A., M. Kumari, and A. Ambesajir, 2011. Studies on antitussive effect of *Tectona grandis* roots using a cough model induced by sulfur dioxide gas in guinea pigs. Int. J. Phytomed., 3: 279-284.
11. Kaushik, A., C. Jijta, J.J. Kaushik, R. Zeray, A. Ambesajir and L. Beyene, 2012. FRAP (ferric reducing ability of plasma) assay and effect of *Diplazium esculentum* (Retz) Sw. (a green vegetable of North India) on central nervous system. Indian J. Nat. Prod. Resour., 3: 228-231.
12. Kaushik, A., T.S. Tesfai, D.K. Barkh, F.K. Ghebremeskel, H.G. Zerihun and S.W. Woldeab, 2020. Evaluation of snake venom's phospholipaseA2 enzyme inhibition activity of *Cyphostemma adenocoule*. Curr. Chem. Biol., 14: 196-202.
13. Kaushik, A., H.A. Abu, I.Y. Tsegay, J.G.H. G/Michael, L.S. Habtesion and Y.F. G/Michael, 2025. Novel anti-epileptic drug design targeting the brain capillary leakage pathway; an *in silico* approach. Sci. Digest, 1: 16-17.
14. Leelananda, S.P. and S. Lindert, 2016. Computational methods in drug discovery. Beilstein J. Org. Chem., 12: 2694-2718.
15. Basu, A., A. Sarkar and U. Maulik, 2020. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. Sci. Rep., Vol. 10. 10.1038/s41598-020-74715-4.
16. Cheemanapalli, S., N. Chinthakunta, N.M. Shaikh, V. Shivaranjani, R.R. Pamuru and S.K. Chitta, 2019. Comparative binding studies of curcumin and tangeretin on up-stream elements of NF-kB cascade: A combined molecular docking approach. Network Model. Anal. Health Inf. Bioinf., Vol. 8. 10.1007/s13721-019-0196-2.
17. Gasmi, A., P.K. Mujawdiya, R. Lysiuk, M. Shanaida and M. Peana *et al.*, 2022. Quercetin in the prevention and treatment of coronavirus infections: A focus on SARS-CoV-2. Pharmaceuticals, Vol. 15. 10.3390/ph15091049.
18. Huang, Z. and X. Liu, 2022. Network pharmacology and molecular docking analysis on targets and mechanisms of berberine in atypical antipsychotic-induced metabolic syndrome. Nat. Prod. Commun., Vol. 17. 10.1177/1934578X221129106.
19. Sahu, R.K., V.V. Verma, A. Kumar, S. Tandon, B.C. Das and S.T. Hedau, 2022. *In silico* prediction and interaction of resveratrol on methyl-CpG binding proteins by molecular docking and MD simulations study. RSC Adv., 12: 11493-11504.
20. Jena, A.B., U.C. Dash and A.K. Duttaroy, 2022. An *in silico* investigation on the interactions of curcumin and epigallocatechin-3-gallate with NLRP3 Inflammasome complex. Biomed. Pharmacother., Vol. 156. 10.1016/j.biopha.2022.113890.



21. Yang, Y., A.A. Alcaraz and J.P. Snyder, 2009. The tubulin-bound conformation of paclitaxel: T-Taxol vs "PTX-NY". *J. Nat. Prod.*, 72: 422-429.
22. Saeed, M.E.M., N. Mahmoud, Y. Sugimoto, T. Efferth and H. Abdel-Aziz, 2018. Betulinic acid exerts cytotoxic activity against multidrug-resistant tumor cells via targeting autocrine motility factor receptor (AMFR). *Front. Pharmacol.*, Vol. 9. 10.3389/fphar.2018.00481.
23. Choi, R.J., A. Roy, H.J. Jung, M.Y. Ali and B.S. Min *et al.*, 2016. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides. *J. Ethnopharmacol.*, 190: 219-230.
24. Rizvi, S.M.D., M.P. Mudagal, S.S. Boregowda, T. Hussain and T. Al Hagbani *et al.*, 2023. The flavonoid hesperidin methyl chalcone as a potential therapeutic agent for cancer therapy: Molecular docking, *in vitro* cytotoxicity, and *in vivo* antitumor activity. *Arabian J. Chem.*, Vol. 16. 10.1016/j.arabjc.2023.104769.
25. Cahayani, W.A., C. Tanuwijaya, L.X. Chi and Y. Mulyastuti, 2019. Antibacterial activity of garlic (*Allium sativum*) extract and molecular docking studies of allicin. *AIP Conf. Proc.*, Vol. 2108. 10.1063/1.5110020.
26. Karunakar, P., V. Krishnamurthy, C.R. Girija, V. Krishna, D.E. Vasundhara, N.S. Begum and A.A. Syed, 2012. *In silico* docking analysis of piperine with cyclooxygenases. *J. Biochem. Tech.*, 3: S122-S127.